About
Vaccines (Lysosomal Associated Membrane Protein)
Areas of Focus
Categories
VaccineVirginia, DC, DE & Maryland
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
5
As Collaborator
4
Total Enrollment
378
By Phase
PHASE1: 7PHASE1/PHASE2: 1PHASE2: 1
By Status
COMPLETED: 6ACTIVE_NOT_RECRUITING: 1TERMINATED: 1RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT05698199Lead Sponsor
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
PHASE1Active, not recruiting
10 participants
Started: Aug 21, 2023 · Completed: Mar 31, 2026
NCT05422781Lead Sponsor
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
PHASE1Completed
6 participants
Started: Jun 13, 2022 · Completed: Jun 27, 2023
NCT04963413Collaborator
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
PHASE1Terminated
6 participants
Started: Jan 13, 2022 · Completed: Sep 28, 2023
NCT05101356Collaborator
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
PHASE1/PHASE2Recruiting
77 participants
Started: Oct 13, 2021 · Completed: Jan 1, 2030
NCT03101267Collaborator
A Dose-finding Study of ASP4070
PHASE2Completed
150 participants
Started: Apr 13, 2017 · Completed: Oct 27, 2018
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...